Screening Functional Biomarkers for Chemosensitivity Using Miniaturized Assays

Novel functional assays for BH3 profiling and T-Cell Activation

Evaluating therapeutic candidates for their efficacy requires tools that can perform rapid quantitative measurement of multiple biological readouts along with the ability to analyze large data sets and provide actionable insights. This webinar will feature the following expert presentations:

1. In personalized medicine, assigning the correct therapeutic for each patient remains challenging, and current static biomarkers like cancer genome sequencing have provided limited insight. Functional markers that test a system’s ability to react to a perturbation, such as BH3 profiling, can provide additional valuable data to guide decisions. This talk by Jeremy Ryan of the Dana-Farber Cancer Institute will highlight how the Intellicyt® iQue Screener Plus can facilitate rapid BH3 profiling using minimal sample thus saving precious primary tumor samples.
   
   
2. In adoptive cell therapy, identification of T-cell subsets and assessing their ex vivo activation is key to developing a scalable process. This presentation delivered by Dr. John O'Rourke will highlight a high throughput flow cytometry-based, multiplexed assay to measure T-cell activation and cytokine secretion in different T-cell subsets.